Cell MedX Corp.

Equities

CMXC

US15115X1072

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:07:57 25/06/2024 pm IST			5-day change	1st Jan Change
0.034 ^USD	-20.93%		+2.41%	+54.55%

15/04	Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	CI
12/03	Cell MedX Corp. announced that it has received $0.075 million in funding	CI

Cell Medx Corp. Reports Earnings Results for the Second Quarter Ended November 30, 2018

January 15, 2019 at 03:10 am IST

Cell MedX Corp. announced earnings results for the second quarter ended November 30, 2018. For the second quarter, the company announced net loss was USD 127,517 compared to USD 181,390 a year ago. For the half year, net loss was USD 370,982 compared to USD 1.014 million a year ago. Basic loss per share was USD 0.01 compared to USD 0.02 a year ago.

Latest news about Cell MedX Corp.

Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	16/04	CI
Cell MedX Corp. announced that it has received $0.075 million in funding	12/03	CI
Cell Medx Corp. Announces Resignation of Brad Hargreaves from the Board of Directors	28/02	CI
Cell MedX Corp. Appoints George Adams as Chairman of the Board	26/02	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	17/01	CI
Cell MedX Corp. Announces Chief Executive Officer Changes	20/12	CI
Cell MedX Corp. Announces Board Appointments	20/12	CI
Cell MedX Corp. Announces Board Changes	09/11	CI
Cell MedX Corp. Reports Earnings Results for the First Quarter Ended August 31, 2023	17/23/17	CI
Cell MedX Corp. Reports Earnings Results for the Full Year Ended May 31, 2023	02/23/02	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	30/23/30	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	19/23/19	CI
Cell MedX Corp. Reports Earnings Results for the First Quarter Ended August 31, 2022	20/23/20	CI
Cell MedX Corp. Reports Earnings Results for the Full Year Ended May 31, 2022	08/23/08	CI
Cell MedX Corp. Auditor Raises 'Going Concern' Doubt	07/23/07	CI
Cell MedX Corp. Appoints Dwayne Yaretz as Chief Executive Officer Replacing Frank McEnulty	27/22/27	CI
Cell Medx Corp Appoints Dwayne Yaretz to the Board of Directors	27/22/27	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	12/22/12	CI
Cell MedX Corp. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021	13/22/13	CI
Cell MedX Corp. Announces FDA Commences Review of Cell MedX's Premarket Notification and Health Canada Renews Class II Medical Device Licenses for Ebalance(R) Systems	15/21/15	CI
Cell Medx Corp. Reports Earnings Results for the First Quarter Ended August 31, 2021	14/21/14	CI
Cell MedX Corp. Files Premarket Notification with the US Food and Drug Administration	17/21/17	CI
Cell Medx Corp. Reports Earnings Results for the Full Year Ended May 31, 2021	31/21/31	CI
Cell MedX Corp. Auditor Raises 'Going Concern' Doubt	30/21/30	CI
Cell MedX Corp. Reports Earnings Results for the Third Quarter Ended February 28, 2021	09/21/09	CI

Chart Cell MedX Corp.

Duration

Period

More charts

Company Profile

Cell MedX Corp. is a biotechnology company. It is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, general health, pain relief, wellness and alleviate complications associated with medical conditions including, diabetes, Parkinsonâs disease, high blood pressure, neuropathy, and kidney function. The Company, through its subsidiary, is engaged in developing and manufacturing therapeutic devices based on its eBalance technology, which harnesses the power of microcurrents and its effects on the human body. The eBalance Pro System and eBalance Home System, are microcurrent electrotherapy systems intended to administer a specific variety of therapeutic microcurrent algorithms for temporary relief of pain associated with sore/aching muscles in the shoulders, waist, back, neck, upper extremities (arms) and lower extremities. Its Microcurrent therapy uses molecular bioelectricity in cell-to-cell signaling.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELL MEDX CORP.	+54.55%	10.11M
MODERNA, INC.	+38.36%	52.73B
LONZA GROUP AG	+39.84%	39B
IQVIA HOLDINGS INC.	-8.63%	38.52B
ALNYLAM PHARMACEUTICALS, INC.	+25.46%	30.38B
CELLTRION, INC.	-11.17%	26.39B
ICON PUBLIC LIMITED COMPANY	+11.44%	26.08B
UNITED THERAPEUTICS CORPORATION	+45.09%	14.15B
MEDPACE HOLDINGS, INC.	+32.93%	12.6B
BIO-TECHNE CORPORATION	-5.30%	11.51B

Other Biotechnology & Medical Research